Jasper Therapeutics, Inc.

JSPR

$0.67

-2.32%

2026-09-04 09:40:47 EDT-$0.02

Healthcare

Biotechnology

NASDAQ

Active Trading

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company’s lead ...

Financial Highlights of JSPR

Profitability trend

Latest / TTM · 6 periods

Gross Margin

0.0%

Net Margin

0.0%

P/E Ratio

-0.43x

n/a

Debt / Equity

0.19

n/a

Current Ratio

1.47

Dividend Yield

0.0%

Understanding

TTM —

Interest coverage is weak

Financial highlights

Latest / TTM · 6 periods

Snapshot

Latest / TTM: 2026-09-04

Gross Margin

0.0%

Net Margin

0.0%

P/E Ratio

-0.43x

Debt / Equity

0.19

Profitability

Profitability table

Metric	2021	2022	2023	2024	2025	2026
Gross MarginGross profit as a percentage of revenue.	0.0%	0.0%	0.0%	0.0%	0.0%	—
Operating MarginOperating income as a percentage of revenue.	0.0%	0.0%	0.0%	0.0%	0.0%	—
Net MarginNet income as a percentage of revenue.	0.0%	0.0%	0.0%	0.0%	0.0%	—
EBITDA MarginEBITDA divided by revenue.	0.0%	0.0%	0.0%	0.0%	0.0%	—
Pre-tax MarginPre-tax profit as a percentage of revenue.	0.0%	0.0%	0.0%	0.0%	0.0%	—

Liquidity & leverage

Liquidity & leverage table

Metric	2021	2022	2023	2024	2025	2026
Current RatioCurrent assets divided by current liabilities.	10.95	5.91	7.19	4.98	2.62	—
Quick RatioLiquid assets divided by current liabilities.	10.95	5.91	7.19	4.98	2.62	—
Cash RatioCash and equivalents divided by current liabilities.	10.56	5.41	7.02	4.70	2.17	—
Debt / AssetsDebt as a share of total assets.	3.1%	7.5%	2.9%	2.3%	3.5%	—
Debt / EquityDebt compared with shareholder equity.	0.04	0.10	0.04	0.03	0.30	—

Operating efficiency

Operating efficiency table

Metric	2021	2022	2023	2024	2025	2026
Receivables TurnoverHow often receivables are collected in a year.	0.00x	0.00x	0.00x	0.00x	0.00x	—
Inventory TurnoverHow often inventory is sold in a year.	0.00x	0.00x	0.00x	0.00x	0.00x	—
Payables TurnoverHow often payables are paid in a year.	0.00x	0.00x	0.00x	0.00x	0.17x	—
Asset TurnoverRevenue generated per dollar of assets.	0.00x	0.00x	0.00x	0.00x	0.00x	—
Working Capital TurnoverRevenue generated per dollar of working capital.	0.00x	0.00x	0.00x	0.00x	0.00x	—

Valuation ratios

Valuation ratios table

Metric	2021	2022	2023	2024	2025	2026
P/E RatioPrice paid for each dollar of earnings.	-2.92x	-0.47x	-1.28x	-4.37x	-0.46x	—
P/B RatioPrice paid for each dollar of book value.	1.29x	0.49x	1.05x	5.06x	8.45x	—
P/S RatioPrice paid for each dollar of sales.	0.00x	0.00x	0.00x	0.00x	0.00x	—
P/FCF RatioPrice paid for each dollar of free cash flow.	-2.48x	-0.38x	-1.57x	-4.94x	-0.45x	—
Dividend YieldAnnual dividend divided by current share price.	0.0%	0.0%	0.0%	0.0%	0.0%	—

Upstream

Lonza Sales AG (Lonza Group)SIX:LONNAmgen Inc.NASDAQ:AMGNSymbio Research (Symbio Proinnovera)Stanford UniversityNational Cancer Institute (NCI) / National Institutes of Health (NIH)Thermo Fisher Scientific Inc.NYSE:TMO Danaher Corporation (Cytiva)NYSE:DHRSartorius AGXETRA:SRT3

Downstream

None (Pre-Commercial Stage)

Proxies

Celldex Therapeutics, Inc.NASDAQ:CLDX Novartis AGNYSE:NVS X4 Pharmaceuticals, Inc.NASDAQ:X4PH

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer

No matching stocks found

Jasper Therapeutics, Inc.

Financial Highlights of JSPR

Financial highlights

Snapshot

Profitability

Liquidity & leverage

Operating efficiency

Valuation ratios

Supply Chain of JSPR

Upstream

Downstream

Proxies

Financial Highlights of JSPR

Financial highlights

Snapshot

Profitability

Liquidity & leverage

Operating efficiency

Valuation ratios

Supply Chain of JSPR

Upstream

Downstream

Proxies